Japan Long-Term Care Pharmaceutical Consumption Market - 2026 - 2033
Description
JAPAN LONG-TERM CARE PHARMACEUTICAL CONSUMPTION MARKET OVERVIEW
The Japan Long-Term Care Pharmaceutical Consumption Market reached US$14.3 Billion in 2024, rising to US$15.22 Billion in 2025 and is expected to reach US$24.99 Billion by 2033, growing at a CAGR of 6.4% from 2026 to 2033.
Long-Term Care (LTC) pharmaceutical consumption is rising in Japan from continued demand for the care of seniors residing in LTC facilities (nursing homes/geriatric hospitals) or being cared for in their home from nursing care. Continued utilization of therapy used to treat patients with chronic illness supports volume-based growth across most major therapy-class segments including Central Nervous System (CNS), Cardiovascular, Diabetes, Osteoporosis, Oncology, and Pain Management. Cost-containment policies have been very successful increasing adoption of generic medicines; the national generic dispensing rate for prescriptions in Japan now exceeds 80% and prescriptions for generic drugs make up more than 80% of all prescriptions written for LTC patients. These trends are evidence of the NHI's (National Health Insurance) continued emphasis on promoting off patent drug substitution in an effort to reduce total health care expenditures. Institutional procurement continues to be the dominant channel for distribution of medications as the vast majority of senior patients in Japan receive their medicines from hospitals or affiliated LTC facilities. Institutions seek to use generics as much as possible in order to keep costs down and provide patients consistent access to all essential therapies.
Demographics remain the primary structural growth driver. Approximately 29% of Japan's population is 65 years or older, the largest proportion among major economies, leading in an increasing burden of dementia, cardiovascular disease, diabetes, cancer, and other chronic disorders that necessitate ongoing pharmaceutical therapy. Rapid expansion in the 75 and 85 age groups drives up polypharmacy demand in LTC settings. CNS medicines are one of the most important therapeutic areas, notably for dementia and neurodegenerative diseases. Stable reimbursement mechanisms overseen by the Ministry of Health, Labour, and Welfare (MHLW) and regulatory oversight by the Pharmaceuticals and Medical Devices Agency (PMDA) continue to ensure pricing discipline, broad access, and long-term structural stability in Japan's long-term care pharmaceutical consumption market.
LONG-TERM CARE PHARMACEUTICAL CONSUMPTION INDUSTRY TRENDS AND STRATEGIC INSIGHTS
• By Drug Type segment, Prescription (Rx) Generics led the Japan Long-Term Care Pharmaceutical Consumption Market, capturing the largest revenue share of 43% in 2025.
JAPAN LONG-TERM CARE PHARMACEUTICAL CONSUMPTION MARKET SIZE AND FUTURE OUTLOOK
• 2025 Market Size: US$15.22 Billion
• 2033 Projected Market Size: US$24.99 Billion
• CAGR (2026–2033): 6.4%
MARKET DYNAMICS
GROWTH OF PALLIATIVE AND END-OF-LIFE CARE
The rise of palliative and end-of-life treatment is a key factor in the increasing use of medications in the long-term care (LTC) market in Japan. The number of aged people with advanced chronic diseases (including those with cancer, heart failure, dementia, and other chronic disorders) is steadily growing as the population ages. As such, the need for comfort-based services continues to increase. Japan is moving from hospital-based death towards death at home or in a long-term care facility, where symptom management is the primary therapeutic outcome for palliative care providers. Palliative care is highly dependent on ongoing medication use, including analgesics to treat pain, sedatives and anxiolytics to address agitation and anxiety, antipsychotics to treat delirium, antiemetics to relieve nausea, and complementary therapies such as inhaled medications to relieve cough and constipation. When prescribing these medications, they are frequently ordered on a regular basis, and doses frequently are increased over time as a patient experiences progressive disease. Therefore, the total amount of medication prescribed per patient will generally be higher than in traditional chronic disease management practices. Furthermore, due to prolonged survival of patients with progressive disease, a longer duration of palliative medication use will lead to an increase in total medication utilization. Thus, the growth of a structured palliative service delivery system in both home and institutional LTC settings creates a structural increase in pharmaceutical demand within the long-term care sector of Japan.
SEGMENTATION ANALYSIS
The Japan Long-Term Care Pharmaceutical Consumption Market is segmented based on drug type, therapeutic area, care delivery setting, distribution channel, and age group.
PRESCRIPTION (RX) GENERICS DRUG TYPE DRIVE SUSTAINED DEMAND FOR LONG-TERM CARE PHARMACEUTICAL CONSUMPTION MARKET
Prescription (Rx) Generics are the largest segment of Japan's long-term care pharmaceutical market, driven by Japan's aging population and the relatively large burden of chronic illnesses in this population. Approximately 29% of the total population of Japan is 65 years of age or older. Commonly, elderly patients in long-term care facilities require ongoing treatment of cardiovascular disease, diabetes, osteoporosis, respiratory illnesses, and neurological disorders. Most frequently, these diseases are treated with off-patent, small-molecule medications, which are available as generics. Japan's National Health Insurance program has promoted the efficient use of generics, allowing the continued increase in generic use. As a result, the rate of generic dispensing has risen to more than 80% by volume in Japan, and even more than 80% of prescriptions in long-term care facilities are written for generic drugs. In the long-term care facilities environment, where many residents have polypharmacy and are treated for long periods of time, access to cost-effective therapies and continuity of care are paramount. Generics are less expensive than branded drugs. However, their very high utilization rates are resulting in generics contributing the greatest amount of dollars to pharmaceutical consumption within long-term care facilities, maintaining both economic viability and providing access to essential therapy for chronic diseases.
COMPETITIVE LANDSCAPE
The Japan Long-Term Care Pharmaceutical Consumption Market is moderately competitive due to the presence of several dominant domestic pharmaceutical innovators, including Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., Eisai Co., Ltd., and Otsuka Pharmaceutical Co., Ltd. These companies continue to be highly competitive due to their comprehensive portfolios of chronic disease therapies that include cardiovascular, CNS, metabolic, oncology, and geriatric-centric chronic therapies—all of which support long-term medication use by older populations. Through their respective specialty biologic and immunology portfolios, Chugai Pharmaceutical Co., Ltd. and Kyowa Kirin Co., Ltd. further increase competition through their oncology and age-related disease drug investment. Other Japanese company, like Sumitomo Pharma Co., Ltd., and Shionogi & Co., Ltd., will compete in the CNS, infectious disease, and specialty chronic treatment markets—all of which promote long-term demand for medications in long-term care facilities.
Multinational companies like Pfizer help drive the oncology and vaccine markets and cardiovascular therapies that are commonly found in the elderly care marketplace. Competitive strategies within the current Japanese long-term care pharmaceutical consumption market include the life cycle management of chronic disease therapies, the expansion of biosimilars, and the development of geriatric-friendly products. Collaboration with community pharmacy networks and coordination with Japan’s generic substitution and pricing initiatives are also key competitive strategies found across the Long-Term Care Pharmaceutical Consumption Market.
KEY DEVELOPMENTS
• In February 2025, approval of Tecentriq® (atezolizumab) in Japan by Chugai Pharmaceutical Co., Ltd. benefits the Japan Long-Term Care Pharmaceutical Consumption Market by increasing the usage of sophisticated immunotherapies among older cancer patients. As a high-cost biologic that requires continued administration and monitoring, it promotes sustained drug demand and increased per-patient spending in hospitals and long-term care facilities, contributing to overall market growth.
• In September, 2025, TAKHZYRO® (lanadelumab) pre-filled pen was approved in Japan for the treatment of hereditary angioedema (HAE). Takeda Pharmaceutical Company Limited received clearance. This breakthrough benefits the Japan Long-Term Care Pharmaceutical Consumption Market by facilitating self-administration of long-term biologic therapy, particularly for older patients. The autoinjector format enhances adherence, lowers hospital visits, and promotes long-term outpatient medicine consumption among Japan's aging population.
WHAT SETS THIS JAPAN LONG-TERM CARE PHARMACEUTICAL CONSUMPTION MARKET INTELLIGENCE REPORT APART
• Latest Data & Forecasts—Comprehensive and up-to-date market intelligence with forecasts through 2033, covering Japan demand by key segmentation, with demand analysis.
• Regulatory Intelligence—Evaluation of Japan's regulatory and reimbursement landscape, including regulation by the Pharmaceuticals and Medical Devices Agency and the Ministry of Health, Labor, and Welfare, NHI pricing adjustments, LTC insurance coverage, generic substitution policy, and pharmacovigilance requirements.
• Competitive Benchmarking—Innovative and generic firms are evaluated based on their geriatric medicine portfolios, pricing strategies, institutional alliances, lifecycle management, and geographic reach in Japan's LTC segment.
• Actionable Strategies & Cost Dynamics—The impact of aging-driven demand, polypharmacy trends, generic entry risks, pricing pressures, and manufacturing cost dynamics on long-term care pharmaceutical consumption.
The Japan Long-Term Care Pharmaceutical Consumption Market reached US$14.3 Billion in 2024, rising to US$15.22 Billion in 2025 and is expected to reach US$24.99 Billion by 2033, growing at a CAGR of 6.4% from 2026 to 2033.
Long-Term Care (LTC) pharmaceutical consumption is rising in Japan from continued demand for the care of seniors residing in LTC facilities (nursing homes/geriatric hospitals) or being cared for in their home from nursing care. Continued utilization of therapy used to treat patients with chronic illness supports volume-based growth across most major therapy-class segments including Central Nervous System (CNS), Cardiovascular, Diabetes, Osteoporosis, Oncology, and Pain Management. Cost-containment policies have been very successful increasing adoption of generic medicines; the national generic dispensing rate for prescriptions in Japan now exceeds 80% and prescriptions for generic drugs make up more than 80% of all prescriptions written for LTC patients. These trends are evidence of the NHI's (National Health Insurance) continued emphasis on promoting off patent drug substitution in an effort to reduce total health care expenditures. Institutional procurement continues to be the dominant channel for distribution of medications as the vast majority of senior patients in Japan receive their medicines from hospitals or affiliated LTC facilities. Institutions seek to use generics as much as possible in order to keep costs down and provide patients consistent access to all essential therapies.
Demographics remain the primary structural growth driver. Approximately 29% of Japan's population is 65 years or older, the largest proportion among major economies, leading in an increasing burden of dementia, cardiovascular disease, diabetes, cancer, and other chronic disorders that necessitate ongoing pharmaceutical therapy. Rapid expansion in the 75 and 85 age groups drives up polypharmacy demand in LTC settings. CNS medicines are one of the most important therapeutic areas, notably for dementia and neurodegenerative diseases. Stable reimbursement mechanisms overseen by the Ministry of Health, Labour, and Welfare (MHLW) and regulatory oversight by the Pharmaceuticals and Medical Devices Agency (PMDA) continue to ensure pricing discipline, broad access, and long-term structural stability in Japan's long-term care pharmaceutical consumption market.
LONG-TERM CARE PHARMACEUTICAL CONSUMPTION INDUSTRY TRENDS AND STRATEGIC INSIGHTS
• By Drug Type segment, Prescription (Rx) Generics led the Japan Long-Term Care Pharmaceutical Consumption Market, capturing the largest revenue share of 43% in 2025.
JAPAN LONG-TERM CARE PHARMACEUTICAL CONSUMPTION MARKET SIZE AND FUTURE OUTLOOK
• 2025 Market Size: US$15.22 Billion
• 2033 Projected Market Size: US$24.99 Billion
• CAGR (2026–2033): 6.4%
MARKET DYNAMICS
GROWTH OF PALLIATIVE AND END-OF-LIFE CARE
The rise of palliative and end-of-life treatment is a key factor in the increasing use of medications in the long-term care (LTC) market in Japan. The number of aged people with advanced chronic diseases (including those with cancer, heart failure, dementia, and other chronic disorders) is steadily growing as the population ages. As such, the need for comfort-based services continues to increase. Japan is moving from hospital-based death towards death at home or in a long-term care facility, where symptom management is the primary therapeutic outcome for palliative care providers. Palliative care is highly dependent on ongoing medication use, including analgesics to treat pain, sedatives and anxiolytics to address agitation and anxiety, antipsychotics to treat delirium, antiemetics to relieve nausea, and complementary therapies such as inhaled medications to relieve cough and constipation. When prescribing these medications, they are frequently ordered on a regular basis, and doses frequently are increased over time as a patient experiences progressive disease. Therefore, the total amount of medication prescribed per patient will generally be higher than in traditional chronic disease management practices. Furthermore, due to prolonged survival of patients with progressive disease, a longer duration of palliative medication use will lead to an increase in total medication utilization. Thus, the growth of a structured palliative service delivery system in both home and institutional LTC settings creates a structural increase in pharmaceutical demand within the long-term care sector of Japan.
SEGMENTATION ANALYSIS
The Japan Long-Term Care Pharmaceutical Consumption Market is segmented based on drug type, therapeutic area, care delivery setting, distribution channel, and age group.
PRESCRIPTION (RX) GENERICS DRUG TYPE DRIVE SUSTAINED DEMAND FOR LONG-TERM CARE PHARMACEUTICAL CONSUMPTION MARKET
Prescription (Rx) Generics are the largest segment of Japan's long-term care pharmaceutical market, driven by Japan's aging population and the relatively large burden of chronic illnesses in this population. Approximately 29% of the total population of Japan is 65 years of age or older. Commonly, elderly patients in long-term care facilities require ongoing treatment of cardiovascular disease, diabetes, osteoporosis, respiratory illnesses, and neurological disorders. Most frequently, these diseases are treated with off-patent, small-molecule medications, which are available as generics. Japan's National Health Insurance program has promoted the efficient use of generics, allowing the continued increase in generic use. As a result, the rate of generic dispensing has risen to more than 80% by volume in Japan, and even more than 80% of prescriptions in long-term care facilities are written for generic drugs. In the long-term care facilities environment, where many residents have polypharmacy and are treated for long periods of time, access to cost-effective therapies and continuity of care are paramount. Generics are less expensive than branded drugs. However, their very high utilization rates are resulting in generics contributing the greatest amount of dollars to pharmaceutical consumption within long-term care facilities, maintaining both economic viability and providing access to essential therapy for chronic diseases.
COMPETITIVE LANDSCAPE
The Japan Long-Term Care Pharmaceutical Consumption Market is moderately competitive due to the presence of several dominant domestic pharmaceutical innovators, including Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., Eisai Co., Ltd., and Otsuka Pharmaceutical Co., Ltd. These companies continue to be highly competitive due to their comprehensive portfolios of chronic disease therapies that include cardiovascular, CNS, metabolic, oncology, and geriatric-centric chronic therapies—all of which support long-term medication use by older populations. Through their respective specialty biologic and immunology portfolios, Chugai Pharmaceutical Co., Ltd. and Kyowa Kirin Co., Ltd. further increase competition through their oncology and age-related disease drug investment. Other Japanese company, like Sumitomo Pharma Co., Ltd., and Shionogi & Co., Ltd., will compete in the CNS, infectious disease, and specialty chronic treatment markets—all of which promote long-term demand for medications in long-term care facilities.
Multinational companies like Pfizer help drive the oncology and vaccine markets and cardiovascular therapies that are commonly found in the elderly care marketplace. Competitive strategies within the current Japanese long-term care pharmaceutical consumption market include the life cycle management of chronic disease therapies, the expansion of biosimilars, and the development of geriatric-friendly products. Collaboration with community pharmacy networks and coordination with Japan’s generic substitution and pricing initiatives are also key competitive strategies found across the Long-Term Care Pharmaceutical Consumption Market.
KEY DEVELOPMENTS
• In February 2025, approval of Tecentriq® (atezolizumab) in Japan by Chugai Pharmaceutical Co., Ltd. benefits the Japan Long-Term Care Pharmaceutical Consumption Market by increasing the usage of sophisticated immunotherapies among older cancer patients. As a high-cost biologic that requires continued administration and monitoring, it promotes sustained drug demand and increased per-patient spending in hospitals and long-term care facilities, contributing to overall market growth.
• In September, 2025, TAKHZYRO® (lanadelumab) pre-filled pen was approved in Japan for the treatment of hereditary angioedema (HAE). Takeda Pharmaceutical Company Limited received clearance. This breakthrough benefits the Japan Long-Term Care Pharmaceutical Consumption Market by facilitating self-administration of long-term biologic therapy, particularly for older patients. The autoinjector format enhances adherence, lowers hospital visits, and promotes long-term outpatient medicine consumption among Japan's aging population.
WHAT SETS THIS JAPAN LONG-TERM CARE PHARMACEUTICAL CONSUMPTION MARKET INTELLIGENCE REPORT APART
• Latest Data & Forecasts—Comprehensive and up-to-date market intelligence with forecasts through 2033, covering Japan demand by key segmentation, with demand analysis.
• Regulatory Intelligence—Evaluation of Japan's regulatory and reimbursement landscape, including regulation by the Pharmaceuticals and Medical Devices Agency and the Ministry of Health, Labor, and Welfare, NHI pricing adjustments, LTC insurance coverage, generic substitution policy, and pharmacovigilance requirements.
• Competitive Benchmarking—Innovative and generic firms are evaluated based on their geriatric medicine portfolios, pricing strategies, institutional alliances, lifecycle management, and geographic reach in Japan's LTC segment.
• Actionable Strategies & Cost Dynamics—The impact of aging-driven demand, polypharmacy trends, generic entry risks, pricing pressures, and manufacturing cost dynamics on long-term care pharmaceutical consumption.
Table of Contents
180 Pages
- 1. Definition and Overview
- 1.1. Study Objectives
- 1.2. Market Definition
- 1.3. Market Scope
- 1.4. Stakeholder Analysis
- 1.5. Currency Considered
- 1.6. Study Period
- 2. Executive Summary
- 2.1. Key Takeaways
- 2.2. Top To Bottom Analysis
- 2.3. Market Share Analysis
- 2.4. Data Points from Key Primary Interviews
- 2.5. Data Points from Key Secondary Databases
- 2.6. Market Snapshot
- 2.7. Geographical Snapshot
- 3. Dynamics
- 3.1. Impacting Factors
- 3.1.1. Drivers
- 3.1.1.1. Growth of Palliative and End-of-Life Care
- 3.1.1.2. Government Push for Dementia Countermeasures
- 3.1.1.3. Chronic Infection Control in LTC Facilities
- 3.1.2. Restraints
- 3.1.2.1. Stringent Drug Price Revisions under National Health Insurance
- 3.1.2.2. Polypharmacy Reduction Policies & Deprescribing Initiatives
- 3.1.3. Opportunity
- 3.1.3.1. Growth of Personalized & Precision Geriatric Medicine
- 3.1.3.2. Preventive Therapeutics for Frailty & Mobility Preservation
- 3.1.3.3. Expansion of Home-Based Medical & Pharmaceutical Services
- 3.1.4. Trends
- 3.1.4.1. Deprescribing & Rational Polypharmacy Management
- 3.1.4.2. Shift Toward Home & Community-Based Care
- 3.1.5. Impact Analysis
- 4. Industry Analysis
- 4.1. Porter’s Five Force Analysis – Japan Long-Term Care Pharmaceutical Consumption Market
- 4.2. Geopolitical & Supply Chain Exposure
- 4.3. Social & Patient-Centric Factors
- 4.4. Economic Factors
- 4.5. Pricing Analysis
- 4.6. Regulatory Analysis
- 4.7. Go-To-Market (GTM) Strategy
- 4.8. Innovation & R&D Trends
- 4.9. Sustainability and ESG Analysis
- 4.10. Polypharmacy & Chronic Medication Management in LTC
- 4.11. Buyer Decision Criteria & Adoption Drivers
- 4.12. DMI Opinion – Strategic Outlook for the Japan Long-Term Care Pharmaceutical Consumption Market
- 5. By Drug Type
- 5.1. Introduction
- 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 5.1.2. Market Attractiveness Index, By Drug Type
- 5.2. Prescription (Rx) Generics
- 5.2.1. Introduction
- 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.3. Specialty Biologics & Biosimilars
- 5.4. Long-Listed Brands
- 5.5. Over-the-Counter (OTC) & Preventive Medicines
- 6. By Therapeutic Area
- 6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
- 6.1.2. Market Attractiveness Index, By Therapeutic Area
- 6.2. Central Nervous System (CNS)
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Cardiovascular
- 6.4. Metabolic & Anti-Diabetic
- 6.5. Oncology
- 6.6. Infectious Disease & Vaccines
- 6.7. Pain Management & Palliative Care
- 7. By Care Delivery Setting
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Care Delivery Setting
- 7.1.2. Market Attractiveness Index, By Care Delivery Setting
- 7.2. Home Healthcare
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Nursing Care & Assisted Living Facilities
- 7.4. Hospice & Palliative Care
- 7.5. Rehabilitation / Post-Acute Care
- 8. By Distribution Channel
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 8.1.2. Market Attractiveness Index, By Distribution Channel
- 8.2. Hospital Pharmacies
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Retail & Community Pharmacies
- 8.4. Institutional LTC Facility Supply
- 8.5. Online & Mail-Order Pharmacies
- 9. By Age Group
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
- 9.1.2. Market Attractiveness Index, By Age Group
- 9.2. 40–64 Years
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. 65–74 Years
- 9.4. 75–84 Years
- 9.5. 85+ years
- 10. Competitive Landscape Analysis
- 10.1. Competitive Scenario
- 10.2. Market Positioning/Share Analysis
- 10.3. Mergers and Acquisitions Analysis
- 10.4. Partner Identification Analysis
- 10.5. Investment & Funding Landscape
- 10.6. Strategic Alliances & Innovation Pipelines
- 11. Company Profiles
- 11.1. Takeda Pharmaceutical Company Limited
- 11.1.1. Company Overview
- 11.1.2. Drug Type Portfolio
- 11.1.3. Revenue Analysis
- 11.1.4. Pricing Analysis
- 11.1.5. SWOT Analysis
- 11.1.6. Recent Developments
- 11.1.6.1. Major Deals
- 11.1.6.2. M&A
- 11.1.6.3. Collaboration
- 11.1.6.4. Acquisition
- 11.1.6.5. Joint Ventures
- 11.1.6.6. Innovations
- 11.1.7. Recent News
- 11.1.7.1. Events
- 11.1.7.2. Conferences
- 11.1.7.3. Symposiums
- 11.1.7.4. Webinars
- 11.2. Daiichi Sankyo Company, Limited
- 11.3. Astellas Pharma Inc.
- 11.4. Eisai Co., Ltd.
- 11.5. Otsuka Pharmaceutical Co., Ltd.
- 11.6. Sumitomo Pharma Co., Ltd.
- 11.7. Shionogi & Co., Ltd.
- 11.8. Chugai Pharmaceutical Co., Ltd
- 11.9. Pfizer
- 11.10. Kyowa Kirin Co., Ltd. (LIST NOT EXHAUSTIVE)
- 12. Japan Long-Term Care Pharmaceutical Consumption Market – Research Methodology
- 12.1. Research Data
- 12.1.1. Secondary Data
- 12.1.2. Primary Data
- 12.1.3. CAGR Analysis
- 12.2. Market Size Estimation Methodology
- 12.2.1. Bottom-Up Approach
- 12.2.2. Top-Down Approach
- 12.3. Market Breakdown & Data Triangulation
- 12.4. Research Assumptions
- 12.5. Limitations
- 13. Appendix
- 13.1. About Us and Services
- 13.2. Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
